Soligenix SNGX 深 沪
已收盘 08-29 16:00:00 美东时间
3.10
+0.040
+1.31%
华盛通- 最 高3.12
- 今 开3.01
- 成交量 25.56万股
- 最 低 2.91
- 昨 收 3.06
- 总市值 1011.93万
- 52周最高 6.2299
- 市盈率 静 --
- 换手率 7.83%
- 52周最低 1.09
- 委 比 97.18%
- 总股本 326.43万
- 历史最高 1219.20
- 量 比 0.62
- 振 幅 6.86%
- 历史最低 1.09
- 每 手 1
- 风险率 3.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
08-21 20:24
Watching Soligenix; Zacks Small-Cap Research Gives Stock $35.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08202025_SNGX_Bautz.pdf
08-20 23:00
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
Why Is Soligenix Stock Soaring On Monday?
Soligenix shares surge after FDA granted orphan drug designation to dusquetide for Behçet's Disease, boosting prospects for rare disease treatment.
08-19 01:03
Soligenix Gains FDA Orphan Drug Designation for Dusquetide
The latest announcement is out from Soligenix ( ($SNGX) ). On August 18, 2025, ...
08-18 21:29
Soligenix shares are trading higher after the company reported better-than-expected Q2 EPS results.
Soligenix shares are trading higher after the company reported better-than-expe...
08-14 23:51
Soligenix Q2 EPS $(0.82) Beats $(0.92) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.92) by 10.87 percent. This is a 37.4 percent increase over losses of $(1.31) per share from the same
08-14 19:39
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
Soligenix Inc. (NASDAQ: SNGX) has been featured in an editorial by NetworkNewsWire (NNW), highlighting its work in advancing treatments for rare diseases, particularly those affecting older adults. The company's HyBryte™ platform, a novel therapy for cutaneous T-cell lymphoma (CTCL), has shown promise, with successful U.S.-based manufacturing of its active ingredient. Soligenix is also advancing other innovative programs, including synthetic hype...
08-07 12:30
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix Inc. (NASDAQ: SNGX) has been featured in an editorial highlighting its advancements in treating rare diseases, particularly cutaneous T-cell lymphoma (CTCL), with its HyBryte(TM) platform. As the U.S. population ages and rare diseases become more prevalent, Soligenix exemplifies domestic innovation in addressing underserved patient populations. With successful manufacturing of HyBryte’s active ingredient and completion of Phase 3 studie...
08-05 12:30
